Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minehiko Inomata

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Molecular and Clinical Oncology|December 12, 2025
TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapyNozomu Murayama, Minehiko Inomata, Daisuke Furukawa, et al.
Cancer Diagnosis & Prognosis|March 4, 2026
Pre-treatment NLR and Changes in NLR Are Associated With Survival Following the Initiation of Immune Checkpoint Inhibitor Therapy in Patients With Non-small Cell Lung CancerMinehiko Inomata, Yuki Matsushiro, Yuki Tanabe, et al.
Medical Oncology (Northwood, London, England)|August 11, 2014
Usefulness of the Palliative Prognostic Index in patients with lung cancerMinehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
Journal of Medical Case Reports|September 6, 2012
Miliary brain metastasis presenting with calcification in a patient with lung cancer: a case reportMinehiko Inomata, Ryuji Hayashi, Kenta Kambara, et al.
Cancer Reports (Hoboken, N.J.)|November 4, 2025
TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung CancerZenta Seto, Minehiko Inomata, Akira Noguchi, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive <i>EGFR</i>-mutant Non-small Cell CarcinomaMinehiko Inomata, Yosuke Kawashima, Ryota Saito, et al.
Anticancer Research|December 8, 2019
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint InhibitorMinehiko Inomata, Tomonobu Kado, Seisuke Okazawa, et al.
Molecular and Clinical Oncology|April 29, 2016
Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinibMinehiko Inomata, Ryuji Hayashi, Hiroaki Tanaka, et al.
Internal Medicine (Tokyo, Japan)|August 8, 2020
Relationship between Patient Characteristics and the Timing of Provision of Explanation about DNAR to Patients with Advanced Lung CancerMinehiko Inomata, Takahiro Hirai, Naoki Takata, et al.
Cancer Diagnosis & Prognosis|April 11, 2022
Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 ExpressionMinehiko Inomata, Naoki Takata, Isami Mizushima, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Molecular and Clinical Oncology|December 12, 2025
TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapyNozomu Murayama, Minehiko Inomata, Daisuke Furukawa, et al.
Cancer Diagnosis & Prognosis|March 4, 2026
Pre-treatment NLR and Changes in NLR Are Associated With Survival Following the Initiation of Immune Checkpoint Inhibitor Therapy in Patients With Non-small Cell Lung CancerMinehiko Inomata, Yuki Matsushiro, Yuki Tanabe, et al.
Medical Oncology (Northwood, London, England)|August 11, 2014
Usefulness of the Palliative Prognostic Index in patients with lung cancerMinehiko Inomata, Ryuji Hayashi, Kotaro Tokui, et al.
Journal of Medical Case Reports|September 6, 2012
Miliary brain metastasis presenting with calcification in a patient with lung cancer: a case reportMinehiko Inomata, Ryuji Hayashi, Kenta Kambara, et al.
Cancer Reports (Hoboken, N.J.)|November 4, 2025
TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung CancerZenta Seto, Minehiko Inomata, Akira Noguchi, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive <i>EGFR</i>-mutant Non-small Cell CarcinomaMinehiko Inomata, Yosuke Kawashima, Ryota Saito, et al.
Anticancer Research|December 8, 2019
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint InhibitorMinehiko Inomata, Tomonobu Kado, Seisuke Okazawa, et al.
Molecular and Clinical Oncology|April 29, 2016
Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinibMinehiko Inomata, Ryuji Hayashi, Hiroaki Tanaka, et al.
Internal Medicine (Tokyo, Japan)|August 8, 2020
Relationship between Patient Characteristics and the Timing of Provision of Explanation about DNAR to Patients with Advanced Lung CancerMinehiko Inomata, Takahiro Hirai, Naoki Takata, et al.
Cancer Diagnosis & Prognosis|April 11, 2022
Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 ExpressionMinehiko Inomata, Naoki Takata, Isami Mizushima, et al.
Pageof 7